Difference between revisions of "Dinaciclib (SCH-727965)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 14: | Line 14: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:CDK inhibitors]] | [[Category:CDK inhibitors]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 23:01, 28 February 2020
Mechanism of action
A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, CDK9, and CDK12.
Preliminary data
Chronic lymphocytic leukemia
- Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Jul;29(7):1524-9. Epub 2015 Feb 24. link to original article link to PMC article PubMed
- Ghia P, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2017 Mar 30;129(13):1876-1878. Epub 2017 Jan 26. link to original article PubMed
Multiple myeloma
- Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8. Epub 2014 Nov 13. link to original article link to PMC article PubMed